Date published: 2025-12-18

1-800-457-3801

SCBT Portrait Logo
Seach Input

DOCK 10 Inhibitors

The class of compounds known as DOCK 10 inhibitors encompasses a group of small molecules that interact with and modulate the activity of the DOCK 10 protein. DOCK 10, a member of the Dedicator of Cytokinesis (DOCK) family of guanine nucleotide exchange factors (GEFs), plays a pivotal role in regulating cell signaling pathways and cytoskeletal dynamics. These inhibitors are designed to bind to specific sites on the DOCK 10 protein, altering its conformation and subsequently influencing its functional activity. DOCK 10, as a GEF, acts as a facilitator for the exchange of GDP (guanosine diphosphate) for GTP (guanosine triphosphate) on Rho GTPases, particularly Rac1 and Cdc42. This exchange is a crucial step in the activation of these GTPases, which in turn regulate various cellular processes such as actin cytoskeleton reorganization, cell migration, and adhesion.

DOCK 10 inhibitors operate by obstructing the nucleotide exchange function of DOCK 10, resulting in the modulation of downstream signaling cascades mediated by Rac1 and Cdc42. This, in turn, influences cellular processes that are reliant on these GTPases' activities, potentially impacting cell motility, morphology, and organization. Researchers have been exploring DOCK 10 inhibitors as tools to dissect the precise contributions of DOCK 10 in cellular processes and to unveil the intricate signaling pathways that it influences. By using these inhibitors, scientists aim to better comprehend the mechanistic intricacies of DOCK 10-mediated cellular functions and the broader implications for cellular physiology. The development and study of DOCK 10 inhibitors shed light on the role of this protein in fundamental cellular processes, opening avenues for unraveling its involvement in normal cellular homeostasis as well as its potential contribution to various diseases or disorders where DOCK 10 dysregulation might play a role.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$25.00
$117.00
$209.00
27
(1)

Tyrosine kinase inhibitor targeting BCR-ABL and c-KIT receptors, used for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs).

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$62.00
$112.00
$214.00
$342.00
74
(2)

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, employed in non-small cell lung cancer (NSCLC) application.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$56.00
$260.00
$416.00
129
(3)

Multi-kinase inhibitor blocking RAF, VEGFR, and PDGFR pathways, used for advanced renal cell carcinoma and hepatocellular carcinoma.

MDV3100

915087-33-1sc-364354
sc-364354A
5 mg
50 mg
$240.00
$1030.00
7
(1)

Androgen receptor antagonist that impedes nuclear translocation and DNA binding, applied in metastatic castration-resistant prostate cancer.

Ibrutinib

936563-96-1sc-483194
10 mg
$153.00
5
(0)

Bruton's tyrosine kinase (BTK) inhibitor, employed for B-cell malignancies like chronic lymphocytic leukemia (CLL) and mantle cell lymphoma.

ABT-199

1257044-40-8sc-472284
sc-472284A
sc-472284B
sc-472284C
sc-472284D
1 mg
5 mg
10 mg
100 mg
3 g
$116.00
$330.00
$510.00
$816.00
$1632.00
10
(0)

B-cell lymphoma 2 (BCL-2) inhibitor promoting apoptosis, used for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) therapy.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$246.00
$490.00
$536.00
16
(1)

Janus kinase (JAK) inhibitor targeting JAK1 and JAK2.

Olaparib

763113-22-0sc-302017
sc-302017A
sc-302017B
250 mg
500 mg
1 g
$206.00
$299.00
$485.00
10
(1)

Poly (ADP-ribose) polymerase (PARP) inhibitor hindering DNA repair, applied in BRCA-mutated ovarian and breast cancer.

Vemurafenib

918504-65-1sc-364643
sc-364643A
10 mg
50 mg
$115.00
$415.00
11
(1)

BRAF kinase inhibitor, specifically for the V600E mutation, used in melanoma therapy.

CH5424802

1256580-46-7sc-364461
sc-364461A
5 mg
50 mg
$191.00
$902.00
(0)

Anaplastic lymphoma kinase (ALK) inhibitor utilized for ALK-positive non-small cell lung cancer (NSCLC).